J. Lieske Et Al. , " Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial," American Society for Nephrology (ASN) Kidney Week 2023. , Pennsylvania, United States Of America, pp.1-2, 2023
Lieske, J. Et Al. 2023. Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial. American Society for Nephrology (ASN) Kidney Week 2023. , (Pennsylvania, United States Of America), 1-2.
Lieske, J., Magen, D., Simkova, E., Devresse, A., Michel, M., Frishberg, Y., ... Bakkaloğlu Ezgü, S. A.(2023). Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial . American Society for Nephrology (ASN) Kidney Week 2023. (pp.1-2). Pennsylvania, United States Of America
Lieske, John Et Al. " Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial," American Society for Nephrology (ASN) Kidney Week 2023. , Pennsylvania, United States Of America, 2023
Lieske, John Et Al. " Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial." American Society for Nephrology (ASN) Kidney Week 2023. , Pennsylvania, United States Of America, pp.1-2, 2023
Lieske, J. Et Al. (2023) . " Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial." American Society for Nephrology (ASN) Kidney Week 2023. , Pennsylvania, United States Of America, pp.1-2.
@conferencepaper{conferencepaper, author={John Lieske Et Al. }, title={ Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial}, congress name={American Society for Nephrology (ASN) Kidney Week 2023. }, city={Pennsylvania}, country={United States Of America}, year={2023}, pages={1-2} }